Summit Therapeutics PLC (LON:SUMM)‘s stock had its “corporate” rating reaffirmed by stock analysts at N+1 Singer in a report issued on Tuesday.
Summit Therapeutics PLC (LON:SUMM) opened at 135.50 on Tuesday. Summit Therapeutics PLC has a 12-month low of GBX 82.66 and a 12-month high of GBX 159.00. The company’s market capitalization is GBX 83.30 million. The firm’s 50-day moving average price is GBX 100.75 and its 200 day moving average price is GBX 105.23.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.